Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas

References

• Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stokh) 1980\(Suppl 92):44–7
   Google Scholar
• Kiken DA, Silverberg NB. Atopic dermatitis in children, part 1: epidemiology, clinical features, and complications. Cutis 2006;78:241–7
   PubMed Web of Science ®Google Scholar
• Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005;6:65–77
   Google Scholar
• Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004;50:391–404
   PubMed Web of Science ®Google Scholar
• Rajka G. Clinical aspects. In: Essential aspects of atopic dermatitis. Berlin: Springer-Verlag, 1989 pp.4–55
   Google Scholar
• Wuthrich B. Epidemiology and natural history of atopic dermatitis. Allergy Clin Immunol Int 1996;8:77–82
   Google Scholar
• Breuer K, Braeutigam M, Kapp A, Werfel T. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004;209:314–20
   PubMed Web of Science ®Google Scholar
• Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:1–24
   Web of Science ®Google Scholar
• Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000;43:649–55
   PubMed Web of Science ®Google Scholar
• Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006;118:3–21
   PubMed Web of Science ®Google Scholar
• Johnson AW, Page DJ. Making sense of sensitive skin. Presented at: Congress of the International Federation of Societies of Cosmetic Chemists; 13–16 Oct 1992; Yokohama, Japan
   Google Scholar
• Kligman AM, Sadiq I, Zhen Y, Crosby M. Experimental studies on the nature of sensitive skin. Skin Res Technol 2006;12:217–22
   PubMed Web of Science ®Google Scholar
• Draelos ZD. Sensitive skin: perceptions, evaluation, and treatment. Am J Contact Dermat 1997;8:67–78
   PubMedGoogle Scholar
• Willis CM, Shaw S, De Lacharrière O, et al. Sensitive skin: an epidemiological study. Br J Dermatol 2001;145:258–63
   Google Scholar
• Cork MJ, Robinson D, Vasilopoulos Y, et al. Predisposition to sensitive skin and atopic eczema. Community Pract 2005;78:440–2
   PubMedGoogle Scholar
• Seidenari S, Francomano M, Mantovani L. Baseline biophysical parameters in subjects with sensitive skin. Contact Dermatitis 1998;38:311–5
   Google Scholar
• Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–6
   Google Scholar
• Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006;118:214–9
   PubMed Web of Science ®Google Scholar
• Irvine AD, McLean WHI. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 2006;126:1200–2
   PubMed Web of Science ®Google Scholar
• Elias PM. Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Exp Dermatol 1996;5:191–201
   PubMedGoogle Scholar
• Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983;80(Suppl):44s–9s
   Google Scholar
• Ogawa H, Yoshiike T. Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment. Pediatr Dermatol 1992;9:383–5
   PubMed Web of Science ®Google Scholar
• Jensen JM, Folster-Holst R, Baranowsky A, et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004;122:1423–31
   PubMed Web of Science ®Google Scholar
• White MI, Jenkinson DM, Lloyd DH. The effect of washing on the thickness of the stratum corneum in normal and atopic individuals. Br J Dermatol 1987;116:525–30
   Google Scholar
• Jakasa I, Verberk MM, Esposito M, et al. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 2007;127:129–34
   PubMed Web of Science ®Google Scholar
• Hata M, Tokura Y, Takigawa M, et al. Assessment of epidermal barrier function by photoacoustic spectrometry in relation to its importance in the pathogenesis of atopic dermatitis. Lab Invest 2002;82:1451–61
   PubMed Web of Science ®Google Scholar
• Proksch E, Fölster-Holst R, Jensen J-M. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006;43:159–69
   PubMed Web of Science ®Google Scholar
• Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Pediatr 2007;19:89–93
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis 2005;76(Suppl 6):7–12
   PubMedGoogle Scholar
• Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198–208
   PubMed Web of Science ®Google Scholar
• MimyX™ Cream: 510(k) summary of the safety and effectiveness. Stiefel Laboratories, Inc., 2005. Available from http://www.fda. gov/cdrh/pdf4/K041342.pdf [Last accessed 11 Oct 2007]
   Google Scholar
• Epiceram® skin barrier emulsion: 510(k) summary. Ceragenix Corporation, 2006. Available from http://www.fda.gov/cdrh/ pdf5/K052643.pdf [Last accessed 11 Oct 2007]33. Abramovits W, Boguniewicz M. A multicenter, randomized, 54. Boguniewicz M, Fiedler VC, Raimer S, et al., for the
   Google Scholar
• Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006;5:236–44
   PubMedGoogle Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005;53:S50–8
   PubMed Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1–191
   PubMedGoogle Scholar
• Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1997;79:197–211
   PubMed Web of Science ®Google Scholar
• Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148(Suppl 63):3–10
   PubMed Web of Science ®Google Scholar
• Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007;156:203–21
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004;44:37–47
   PubMed Web of Science ®Google Scholar
• Kao JS, Fluhr JW, Man M-Q, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003;120:456–64
   Google Scholar
• National Institute for Clinical Excellence. Technology Appraisal 81. Frequency of application of topical corticosteroids for atopic eczema. London, England: National Institute for Clinical Excellence, 2004
   Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1–15
   PubMed Web of Science ®Google Scholar
• Desonate™ Gel 0.05% prescribing information. Carlsbad, CA, USA: SkinMedica, 2006
   Google Scholar
• Cutivate® prescribing information. Pittsburgh, PA, USA: GlaxoSmithKline; 2002
   Google Scholar
• Eichenfield LF, Miller BH. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. J Am Acad Dermatol 2006;54: 715–7
   Google Scholar
• Friedlander SF, Hebert AA, Allen DB, for the Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46: 387–93
   Google Scholar
• Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528–37
   Google Scholar
• Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr 2006;149:378–82
   Google Scholar
• Tan M-H, Lebwohl M, Esser AC, Wei H. The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol 2001;45: 392–6
   Google Scholar
• Vergnanini A, Aoki V, Madi J. Comparative effects ofpimecrolimus cream vehicle and 3 commercially available moisturizers on skin hydration and transepidermal water loss [AAD poster abstract P577]. J Am Acad Dermatol 2007;56 (Suppl S2):AB60
   Google Scholar
• Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271–7
   PubMed Web of Science ®Google Scholar
• Meurer M, Fartasch M, Albrecht G, et al., for the CASM-DE-01 Study Group. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365–72
   Google Scholar
• Kang S, Lucky AW, Pariser D, et al., and the Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58–64
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fiedler VC, Raimer S, et al., for the Pediatric Tacrolimus Study Group. A randomized, vehiclecontrolled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102: 637–44
   Google Scholar
• Reitamo S, Wollenberg A, Schöpf E, et al., for the European Tacrolimus Ointment Study Group. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136: 999–1006
   Google Scholar
• Paller A, Eichenfield LF, Leung DYM, et al., and the Tacrolimus Ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:S47–57
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Bieber T, Schopf E, et al., for the European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816–21
   Google Scholar
• Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495–504
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M, et al., for the Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2. Available from http://www. pediatrics.org/cgi/content/full/110/1/e2 [Last accessed 10 Oct 2007]
   Google Scholar
• Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005;52: 240–6
   Google Scholar
• Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004;15: 169–78
   Google Scholar
• Lübbe J, Friedlander SF, Cribier B, et al., on behalf of the NOBEL (New Online Based ELidel Study Group). Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006;7: 121–31
   Google Scholar
• Weise-Riccardi S, Calvieri S, Ortonne J-P, et al. Randomized vehicle-controlled trial of pimecrolimus cream 1% in adult patients with mild to moderate head and neck atopic dermatitis intolerant of, or dependent on topical corticosteroids. Poster presented at: 67th Annual Meeting of the Society for Investigative Dermatology; 3–7 May 2006; Philadelphia, PA, USA
   Google Scholar
• Jensen J, Pfeiffer S, Witt M, et al. Pimecrolimus but not betamethasonetreatment improves stratum corneum barrier structure in atopic dermatitis. Abstract presented at: 68th Annual Meeting of the Society for Investigative Dermatology; 9–12 May 2007; Los Angeles, CA, USA
   Google Scholar
• Proksch E, Jensen J-M, Elias P, Folster-Holst R. Substantial improvement of the skin barrier in atopic dermatitis after treatment with pimecrolimus but not with betamethasone. Abstract presented at: 65th Annual Meeting of the American Academy of Dermatology; 2–6 Feb 2007; Washington, DC, USA
   Google Scholar
• Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004;150: 1174–81
   Google Scholar
• Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144: 507–13
   Google Scholar
• Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396–8
   PubMed Web of Science ®Google Scholar
• Protopic® prescribing information. Deerfield, IL, USA: Astellas Pharma US, Inc., 2006
   Google Scholar
• Elidel® prescribing information. East Hanover, NJ, USA: Novartis Pharmaceuticals Corporation; 2006
   Google Scholar
• Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004;151(Suppl 70):3–27
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330:516
   PubMed Web of Science ®Google Scholar
• Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969–73
   PubMed Web of Science ®Google Scholar
• Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29–35
   Google Scholar
• Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005;124:695–9
   PubMed Web of Science ®Google Scholar
• Thaci D, Steinmeyer K, Ebelin M-E, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology 2003;207: 37–42
   Google Scholar
• Van Leent EJM, Ebelin M-E, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002;204: 63–8
   Google Scholar
• Drug Regulatory Affairs: Elidel (pimecrolimus) Cream 1%. NDA 21–302 Briefing Document. January 25, 2005
   Google Scholar
• Food and Drug Administration, Pediatric Advisory Committee. Discussion topic: risk evaluation, labeling, risk communication, and dissemination of information on potential cancer risk among pediatric patients treated for atopic dermatitis with topical dermatological immunosuppressants. Fujisawa Healthcare, Inc. February 15, 2005. Background Package
   Google Scholar
• Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:174–87
   Google Scholar
• Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818–23
   PubMed Web of Science ®Google Scholar
• Fonacier L, Spergel J, Charlesworth EN, et al. Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005;115:1249–53
   PubMed Web of Science ®Google Scholar
• Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors. Position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005;19:663–71
   PubMed Web of Science ®Google Scholar